About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Hepatitis D Market Research Report 2023-2035 | Epidemiological Analysis, Key Trends, Regulatory Landscape, Pipeline Analysis, Market Dynamics - ResearchAndMarkets.com

The "Hepatitis D Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnostic Method, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis D market is experiencing steady growth, driven by several key factors. Firstly, the increasing diagnosis rates of hepatitis D, particularly in regions with a high prevalence of hepatitis B virus (HBV) infections, have led to a greater demand for effective treatment solutions. Secondly, advancements in diagnostic technologies, including improved genetic testing, serological assays, and nucleic acid testing, have enabled earlier and more accurate detection of hepatitis D, leading to better patient outcomes and enhanced disease management. Thirdly, the approval and introduction of novel therapies, such as bulevirtide and antiviral agents targeting HDV replication, have expanded treatment options, offering more targeted and effective solutions for managing chronic hepatitis D.

Additionally, rising awareness among healthcare professionals and patients about the risks associated with co-infection of HBV and HDV has led to more diagnoses, which further increases the need for specialized therapies. Furthermore, the growing investment in research and development, supported by both public and private sectors, is accelerating the discovery of new antiviral therapies and biomarkers, contributing to the ongoing market growth.

The hepatitis D market faces several challenges, including the high cost of treatment, which can limit patient access, particularly in low- and middle-income regions. Novel treatments are expensive, and while they are effective, their cost remains a barrier for many patients. Additionally, the rarity of hepatitis D means that expertise and experience in managing the disease are limited, which can lead to delayed diagnosis and suboptimal treatment outcomes. The complexity of the disease, particularly its co-infection with hepatitis B, requires a multidisciplinary approach to treatment, further complicating disease management. Regulatory hurdles, such as long approval timelines for new therapies, can also delay patient access to potentially life-saving treatments.

Recent advancements in hepatitis D treatment have introduced new therapeutic options, such as bulevirtide, which effectively inhibits HDV replication. Other emerging therapies are focusing on targeting viral entry and other aspects of the viral lifecycle. Additionally, research into RNA-based therapies, such as RNA interference and gene therapy, is showing promise in offering long-term solutions for hepatitis D. These therapies aim to address the underlying causes of the disease, potentially providing a cure for patients with chronic HDV infections. Ongoing research into liver transplantation and other novel treatments also holds promise for patients with severe liver damage caused by hepatitis D.

The competitive landscape in the hepatitis D market is evolving, with key players such as Gilead Sciences, GSK plc, Janssen Pharmaceuticals and other pharmaceutical companies working on developing new treatments. Several emerging biotech companies are focusing on developing next-generation therapies, including antiviral agents, RNA-based treatments, and gene therapies, with the potential to address unmet needs in the treatment of hepatitis D. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are becoming more common, with a shared focus on advancing personalized medicine and improving long-term outcomes for hepatitis D patients.

Key Topics Covered:

1. Global Hepatitis D Market: Industry Analysis

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis

1.3 Key Market Trends

1.3.1 Impact Analysis

1.4 Regulatory Landscape

1.5 Pipeline Analysis

1.6 Market Dynamics

1.6.1 Overview

1.6.2 Market Drivers

1.6.3 Market Restraints

1.6.4 Market Opportunities

2. Global Hepatitis D Market (by Treatment Type), Value ($million), 2023-2035

2.1 Antiviral Medications

2.2 Immunotherapies

2.3 Combination Therapies

3. Global Hepatitis D Market (by Diagnostic Methods), Value ($million), 2023-2035

3.1 Blood Tests

3.2 Imaging Techniques

4. Global Hepatitis D Market (by Region), Value ($Million), 2023-2035

4.1 North America

4.1.1 Market Dynamics

4.1.2 Market Sizing and Forecast

4.1.3 North America Hepatitis D Market, by Country ($Million), 2023-2035

4.1.3.1 U.S.

4.1.3.2 Canada

4.2 Europe

4.2.1 Market Dynamics

4.2.2 Market Sizing and Forecast

4.2.3 Europe Hepatitis D Market, by Country ($Million), 2023-2035

4.2.3.1 U.K.

4.2.3.2 France

4.2.3.3 Germany

4.2.3.4 Italy

4.2.3.5 Spain

4.2.3.6 Rest-of-Europe

4.3 Asia-Pacific

4.4 Rest-of-the-World

5. Competitive Landscape and Company Profiles

5.1 Competitive Landscape

5.1.1 Mergers and Acquisitions

5.1.2 Partnership, Alliances and Business Expansion

5.1.3 New Offerings

5.1.4 Regulatory Activities

5.1.5 Funding Activities

5.2 Company Profiles

5.2.1 Overview

5.2.2 Top Products / Product Portfolio

5.2.3 Top Competitors

5.2.4 Target Customers/End-Users

5.2.5 Key Personnel

5.2.6 Analyst View

  • Antios Therapeutics
  • Aurobindo Pharma Limited
  • Eiger Biopharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences
  • GSK plc
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan N.V
  • Replicor

For more information about this report visit https://www.researchandmarkets.com/r/726tiw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.